HK1152947A1 - Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6 - Google Patents

Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6

Info

Publication number
HK1152947A1
HK1152947A1 HK11106921.8A HK11106921A HK1152947A1 HK 1152947 A1 HK1152947 A1 HK 1152947A1 HK 11106921 A HK11106921 A HK 11106921A HK 1152947 A1 HK1152947 A1 HK 1152947A1
Authority
HK
Hong Kong
Prior art keywords
trpv6
inhibiting
cancer treatment
calcium channel
channel activity
Prior art date
Application number
HK11106921.8A
Other languages
English (en)
Chinese (zh)
Inventor
John M Stewart
Original Assignee
Soricimed Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soricimed Biopharma Inc filed Critical Soricimed Biopharma Inc
Publication of HK1152947A1 publication Critical patent/HK1152947A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11106921.8A 2008-03-19 2011-07-05 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6 HK1152947A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790308P 2008-03-19 2008-03-19
PCT/CA2009/000343 WO2009114943A1 (fr) 2008-03-19 2009-03-18 Compositions peptidiques pour le traitement du cancer par inhibition de l'activité du canal calcique trpv6

Publications (1)

Publication Number Publication Date
HK1152947A1 true HK1152947A1 (en) 2012-03-16

Family

ID=41090452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106921.8A HK1152947A1 (en) 2008-03-19 2011-07-05 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6

Country Status (7)

Country Link
US (4) US8211857B2 (fr)
EP (1) EP2268665B1 (fr)
JP (1) JP5749154B2 (fr)
CA (1) CA2718949C (fr)
ES (1) ES2530091T3 (fr)
HK (1) HK1152947A1 (fr)
WO (1) WO2009114943A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2268665B1 (fr) 2008-03-19 2014-11-12 Soricimed Biopharma Inc. Compositions peptidiques pour le traitement du cancer par inhibition de l'activité du canal calcique trpv6
MX2012000086A (es) 2009-06-26 2012-06-12 Soricimed Biopharma Inc Peptidos derivados de soricidi y metodos para la la deteccion de canceres trpv-6 y suministro de farmaco.
WO2014040178A1 (fr) * 2012-09-14 2014-03-20 Stewart John M Agonistes de trpv3 pour le traitement de maladies cutanées
US10954278B2 (en) 2015-11-02 2021-03-23 University Of New Brunswick Peptides for the treatment of resorptive bone disease
EP3716991A4 (fr) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. Inhibiteurs de trpv6 et polythérapies pour le traitement de cancers
CN113072634B (zh) * 2021-03-17 2022-07-12 西安交通大学 一种胞膜瞬时受体电位c6通道免疫原性短肽及其疫苗和抗心室纤维化的制药应用
AU2022365387A1 (en) 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JPH10236963A (ja) 1997-02-26 1998-09-08 Sagami Chem Res Center カルシウムチャンネル拮抗剤
US6326020B1 (en) 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
US6946475B1 (en) * 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
WO2000059882A1 (fr) * 1999-04-07 2000-10-12 Gray Lloyd S Bloqueurs du canal calcium anticancereux
US6534642B1 (en) 1999-07-09 2003-03-18 Matthias A. Hediger Compositions corresponding to a calcium transporter and methods of making and using same
EP1366158B1 (fr) 2000-07-28 2008-05-21 Ulrich Wissenbach Marqueurs trp8 associes au cancer
ATE384078T1 (de) * 2002-11-18 2008-02-15 Bioprospecting Nb Inc Paralytisches peptide von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
EP2268665B1 (fr) 2008-03-19 2014-11-12 Soricimed Biopharma Inc. Compositions peptidiques pour le traitement du cancer par inhibition de l'activité du canal calcique trpv6

Also Published As

Publication number Publication date
US8211857B2 (en) 2012-07-03
JP2011517442A (ja) 2011-06-09
EP2268665A4 (fr) 2011-05-18
US20140187493A1 (en) 2014-07-03
CA2718949A1 (fr) 2009-09-24
WO2009114943A1 (fr) 2009-09-24
US20160206694A1 (en) 2016-07-21
US20120316119A1 (en) 2012-12-13
US20110071089A1 (en) 2011-03-24
JP5749154B2 (ja) 2015-07-15
EP2268665B1 (fr) 2014-11-12
CA2718949C (fr) 2021-05-04
US8618058B2 (en) 2013-12-31
EP2268665A1 (fr) 2011-01-05
ES2530091T3 (es) 2015-02-26
US10058587B2 (en) 2018-08-28
US9303077B2 (en) 2016-04-05

Similar Documents

Publication Publication Date Title
IL229878A0 (en) Compounds for the treatment of cancer
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
IL199907A0 (en) Composition for treatment of pancreatic cancer
EP1996612A4 (fr) Compositions destinee au traitement des cancers
EP2152722A4 (fr) Compositions comportant des agents therapeutiques mir34 pour traiter le cancer
PT2310034E (pt) Péptidos para o tratamento de beta-amiloidoses
HK1152947A1 (en) Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6
IL209156A0 (en) Opioid composition for treating skin lesions
IL213398A0 (en) Compounds for treating cancer
EP2327402A4 (fr) Composition contenant 4-o-méthylhonokiol pour traiter ou prévenir des maladies liées aux amyloïdes
IL211904A0 (en) Composition for treating disese
EP2374463A4 (fr) Composition pour l'amélioration de la radiothérapie pour le cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2255825A4 (fr) Composition pour prévenir ou traiter des maladies du cerveau
EP2174956A4 (fr) Compositions de traitement antifibrinolitique
EP1986656A4 (fr) Composes de withacnistine pour le traitement du cancer
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
EP2473506A4 (fr) Composés et compositions pour le traitement du cancer
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0707556D0 (en) Treatment for cancer
EP2214485A4 (fr) Méthodes de traitement du cancer
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
EP2329824A4 (fr) Nouvelle composition pharmaceutique pour le traitement de la douleur nociceptive
GB0817056D0 (en) Polypeptide for treatment of cancer
GB0914322D0 (en) Compounds for treating cancer